StockNews.AI
WGS
StockNews.AI
63 days

GENEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire investigates GeneDx for possible federal law violations. 2. Grizzly Research claims GeneDx engaged in fraudulent revenue inflation tactics. 3. CEO and CFO consistently sold shares, hinting at insider concerns. 4. GeneDx's stock price dropped 6.72% following fraud allegations. 5. Investors may reconnect if they suffered losses related to GeneDx.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations of widespread fraud and insider selling significantly undermine investor confidence, reflecting negatively on GeneDx's stability. Historical examples show that similar allegations often lead to prolonged declines in stock price.

How important is it?

The investigation into potential fraud directly impacts GeneDx’s reputation and financial health, making it a highly relevant topic for WGS investors.

Why Short Term?

Immediate market reaction to fraud allegations typically affects stock prices quickly, as seen with GeneDx's recent 6.72% drop. Indications of ongoing legal issues will continue to pressure the stock in the near term.

Related Companies

WGSAHLTLFTLEPRLB
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) on behalf of GeneDx stockholders. Our investigation concerns whether GeneDx has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On February 5, 2025, Grizzly Research ("Grizzly") published a report entitled "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud". The Grizzly report asserted, among other things, that GeneDx's "growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue"; that "[t]estimonies from former employees and ongoing litigation suggest that GeneDx has inflated its revenue through an illegal practice known as ‘code stacking'", which "enables the company to bill insurance providers for services that do not meet the required criteria"; and that "CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, without ever engaging in open market purchases", a "pattern suggest[ing] that insiders may be aware of an imminent risk that will significantly impact the company." On this news, GeneDx's stock price fell $4.84 per share, or 6.72%, to close at $67.18 per share on February 5, 2025. If you purchased or otherwise acquired GeneDx shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News